News | September 03, 2009

Ochsner Replaces Heart Valve Without Open Heart Surgery

September 3, 2009 – On Tuesday, Aug. 11, an 82-year old New Orleans resident with severe aortic stenosis successfully had a heart valve replaced at Ochsner Medical Center using the same technique as angioplasty, a far cry from the traditional open heart procedure.

Patients who are considered high-risk or nonoperable for conventional open heart valve surgery now have a potential new research option available regionally only through The John Ochsner Heart & Vascular Institute. The center is the only hospital in the Gulf South selected to participate as an FDA investigative site in the PARTNER (Placement of AoRTic traNscathetER valves) clinical trial, evaluating the Edwards SAPIEN transcatheter aortic heart valve in patients who are at high risk for open heart surgery and surgical valve repair.

Annually, some 200,000 people in the U.S. need a new heart valve. "This dramatic new procedure offers a new lease on life for patients with severe aortic stenosis, severe narrowing of the heart valve, and highlights Ochsner's continuing efforts to place patient care first by offering a minimally invasive alternative to open heart surgery which may reduce morbidity and recovery time," said Stephen Ramee, M.D., Ochsner cardiologist and clinical investigator.

The purpose of the PARTNER study is to determine the safety and effectiveness of the Edwards SAPIEN Transcatheter Heart Valve device and delivery systems (leg: transfemoral and chest: transapical). Amazingly, the percutaneous arm of this study makes no cuts in the chest at all. A catheter carrying a tissue valve built into a metal stent a half an inch in diameter is threaded up the artery from the leg to the aortic valve, where it positions the new valve within the damaged one. This procedure is performed in a state-of-the-art cath lab on a "beating heart," without the need for bypass machine, which can pose additional risks. As with any research trial, no guarantees can be made about outcomes. Study benefits and risks along with alternatives are reviewed in detail before a person enrolls.

Ochsner was chosen for the trial due to its expertise in valve replacement surgery and vast experience in interventional procedures. "This is an interdisciplinary study in which Ochsner's cardiovascular medicine, cardiothoracic surgery, and anesthesia departments are working collaboratively, using the best techniques from all three specialties, to advance the standard of care for our patients," said Gene Parrino, M.D., coinvestigator in the trial.

A prospective randomized study, PARTNER has two separate treatment arms. The surgical arm features 690 high-risk patients who are candidates for conventional open-heart surgery. Randomized, these patients will receive either the Edwards SAPIEN transcatheter heart valve or an Edwards surgical valve to demonstrate that the transcatheter heart valve is not statistically inferior to conventional surgery. The non-surgical arm will feature 350 nonoperative patients who will be evenly randomized to receive either the Edwards SAPIEN transcatheter heart valve or appropriate medical therapy in order to demonstrate that the transcatheter heart valve is statistically superior to medical management.

Related Content

Abbott Receives FDA Approval for Third-Generation MitraClip Device
Technology | Heart Valve Technology | July 18, 2018
July 18, 2018 — Abbott announced it received approval from the U.S.
Videos | Heart Valve Technology | July 18, 2018
Jonathon Leipsic, M.D., FSCCT, professor of radiology and cardiology at the University of British Columbia, Vancouver
Videos | Heart Valve Technology | July 10, 2018
Ori Ben-Yehuda, M.D., executive director of the Cardiovascular Research Foundation Clinical Trial Center, discusses t
Videos | Heart Valve Technology | July 05, 2018
Rebecca Hahn, M.D., professor of medicine and director of interventional echocardiography, Columbia University Medica
Henry Ford Hospital First in Michigan to Perform Cardioband Mitral Valve Procedure

An angiography image showing the catheter-based implantation of the Cardioband annuloplasty ring using corkscrew shaped anchors.

News | Heart Valve Technology | June 13, 2018
Henry Ford Hospital is one of 17 U.S. trial sites using a catheter-based procedure approved in Europe to repair a leaky...
Abbott Portico transcatheter aortic valve replacement (TAVR) performed well PORTICO I real-world study. #EuroPCR
News | Heart Valve Technology | June 01, 2018
June 1, 2018 –  Use of the Abbott Portico transcatheter aortic valve replacement (TAVR) therapy was associated with e
Tendyne Transcatheter Mitral Valve Replacement Device Demonstrates Positive 30-Day Outcomes
News | Heart Valve Technology | May 25, 2018
Abbott announced favorable outcomes from the first 100 patients treated in a global study of its Tendyne Transcatheter...
A 3-D printed aortic root with an simulated implant of an Edwards Sapien TAVR valve. New clinical data points to length-of-stay as a new predictor of outcomes in TAVR patients. Image from Henry Ford Hospital.

A 3-D printed aortic root with an simulated implant of an Edwards Sapien TAVR valve. New clinical data points to length-of-stay as a new predictor of outcomes in TAVR patients. Image from Henry Ford Hospital. 

Feature | Heart Valve Technology | May 14, 2018
May 14, 2018 – A new study finds patients who stay in the hospital for more than 72 hours when undergoing trans-femor
The use of 3-D printed hearts from patients' pre-TAVR planning CT scans have improved outcomes of procedures at the University of Minnesota. Clearly identifying where calcium is located on the valves prior to TAVR device implantation has helped reduce the incidence of paravalvular leak.  #SCAI, #SCAI2018

The use of 3-D printed hearts from patients' pre-TAVR planning CT scans have improved outcomes of procedures at the University of Minnesota. Clearly identifying where calcium is located on the valves prior to TAVR device implantation has helped reduce the incidence of paravalvular leak.

News | Heart Valve Technology | May 14, 2018
May 14, 2018 – A new study examines the effectiveness of 3-D printing technology and computer modeling to predict par
First-Ever Risk Tool Helps Predict TAVR Readmission Rates in 2018 SCAI late-breaking study. #SCAI, #SCAI2018
News | Heart Valve Technology | May 11, 2018
A new study looked at the effectiveness of a novel risk tool to predict 30-day readmission rates in patients undergoing...
Overlay Init